Knowledge and therapeutic gaps: A public health problem in the rare coagulation disorders population

Amy D. Shapiro, J. Michael Soucie, Flora Peyvandi, Diane J. Aschman, Donna M. Dimichele

Research output: Contribution to journalArticle

Abstract

Rare coagulation disorders (RCDs) present a considerable and multifaceted public health risk. Although inherited RCDs affect a minor segment of any local healthcare delivery system, their global impact is major and highlight the challenges of delivering healthcare services to any rare disease population. These include but are not limited to: (1) a general lack of knowledge about and familiarity with the genetic and clinical implications of the disorder among affected patients, and both urgent and specialty care providers; (2) the potential for preventable morbidity and mortality related to delayed diagnosis and treatment; (3) the lack of safe and effective therapies; and (4) minimal research activity to establish and improve standards of care. A multiagency national partnership has established an approach to address these problems through development of a clinical, genetic, and treatment-related web-based data-collection tool that will: (1) generate a reliable, sufficient knowledge base for these disorders; (2) facilitate new product licensure through subject identification and access to comparative historical treatment data; and (3) serve as an effective tool for outcomes research and post-licensure product surveillance. To maximize impact, this database is being harmonized with a European data-collection effort. Database development and harmonization is in progress. A resource library was completed and disseminated to major national and international bleeding disorder websites to provide state-of-the-art patient and provider education on each RCD. We believe that this model is effective and adaptable to other rare conditions.

Original languageEnglish
JournalAmerican Journal of Preventive Medicine
Volume41
Issue number6 SUPPL.4
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Public Health
Licensure
Delivery of Health Care
Population
Inherited Blood Coagulation Disorders
Databases
Knowledge Bases
Delayed Diagnosis
Patient Education
Therapeutics
Standard of Care
Ambulatory Care
Rare Diseases
Libraries
Outcome Assessment (Health Care)
Hemorrhage
Morbidity
Mortality
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Knowledge and therapeutic gaps : A public health problem in the rare coagulation disorders population. / Shapiro, Amy D.; Soucie, J. Michael; Peyvandi, Flora; Aschman, Diane J.; Dimichele, Donna M.

In: American Journal of Preventive Medicine, Vol. 41, No. 6 SUPPL.4, 12.2011.

Research output: Contribution to journalArticle

Shapiro, Amy D. ; Soucie, J. Michael ; Peyvandi, Flora ; Aschman, Diane J. ; Dimichele, Donna M. / Knowledge and therapeutic gaps : A public health problem in the rare coagulation disorders population. In: American Journal of Preventive Medicine. 2011 ; Vol. 41, No. 6 SUPPL.4.
@article{702be2bb6ca0426b8c0eab40aec0014c,
title = "Knowledge and therapeutic gaps: A public health problem in the rare coagulation disorders population",
abstract = "Rare coagulation disorders (RCDs) present a considerable and multifaceted public health risk. Although inherited RCDs affect a minor segment of any local healthcare delivery system, their global impact is major and highlight the challenges of delivering healthcare services to any rare disease population. These include but are not limited to: (1) a general lack of knowledge about and familiarity with the genetic and clinical implications of the disorder among affected patients, and both urgent and specialty care providers; (2) the potential for preventable morbidity and mortality related to delayed diagnosis and treatment; (3) the lack of safe and effective therapies; and (4) minimal research activity to establish and improve standards of care. A multiagency national partnership has established an approach to address these problems through development of a clinical, genetic, and treatment-related web-based data-collection tool that will: (1) generate a reliable, sufficient knowledge base for these disorders; (2) facilitate new product licensure through subject identification and access to comparative historical treatment data; and (3) serve as an effective tool for outcomes research and post-licensure product surveillance. To maximize impact, this database is being harmonized with a European data-collection effort. Database development and harmonization is in progress. A resource library was completed and disseminated to major national and international bleeding disorder websites to provide state-of-the-art patient and provider education on each RCD. We believe that this model is effective and adaptable to other rare conditions.",
author = "Shapiro, {Amy D.} and Soucie, {J. Michael} and Flora Peyvandi and Aschman, {Diane J.} and Dimichele, {Donna M.}",
year = "2011",
month = "12",
doi = "10.1016/j.amepre.2011.09.021",
language = "English",
volume = "41",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",
number = "6 SUPPL.4",

}

TY - JOUR

T1 - Knowledge and therapeutic gaps

T2 - A public health problem in the rare coagulation disorders population

AU - Shapiro, Amy D.

AU - Soucie, J. Michael

AU - Peyvandi, Flora

AU - Aschman, Diane J.

AU - Dimichele, Donna M.

PY - 2011/12

Y1 - 2011/12

N2 - Rare coagulation disorders (RCDs) present a considerable and multifaceted public health risk. Although inherited RCDs affect a minor segment of any local healthcare delivery system, their global impact is major and highlight the challenges of delivering healthcare services to any rare disease population. These include but are not limited to: (1) a general lack of knowledge about and familiarity with the genetic and clinical implications of the disorder among affected patients, and both urgent and specialty care providers; (2) the potential for preventable morbidity and mortality related to delayed diagnosis and treatment; (3) the lack of safe and effective therapies; and (4) minimal research activity to establish and improve standards of care. A multiagency national partnership has established an approach to address these problems through development of a clinical, genetic, and treatment-related web-based data-collection tool that will: (1) generate a reliable, sufficient knowledge base for these disorders; (2) facilitate new product licensure through subject identification and access to comparative historical treatment data; and (3) serve as an effective tool for outcomes research and post-licensure product surveillance. To maximize impact, this database is being harmonized with a European data-collection effort. Database development and harmonization is in progress. A resource library was completed and disseminated to major national and international bleeding disorder websites to provide state-of-the-art patient and provider education on each RCD. We believe that this model is effective and adaptable to other rare conditions.

AB - Rare coagulation disorders (RCDs) present a considerable and multifaceted public health risk. Although inherited RCDs affect a minor segment of any local healthcare delivery system, their global impact is major and highlight the challenges of delivering healthcare services to any rare disease population. These include but are not limited to: (1) a general lack of knowledge about and familiarity with the genetic and clinical implications of the disorder among affected patients, and both urgent and specialty care providers; (2) the potential for preventable morbidity and mortality related to delayed diagnosis and treatment; (3) the lack of safe and effective therapies; and (4) minimal research activity to establish and improve standards of care. A multiagency national partnership has established an approach to address these problems through development of a clinical, genetic, and treatment-related web-based data-collection tool that will: (1) generate a reliable, sufficient knowledge base for these disorders; (2) facilitate new product licensure through subject identification and access to comparative historical treatment data; and (3) serve as an effective tool for outcomes research and post-licensure product surveillance. To maximize impact, this database is being harmonized with a European data-collection effort. Database development and harmonization is in progress. A resource library was completed and disseminated to major national and international bleeding disorder websites to provide state-of-the-art patient and provider education on each RCD. We believe that this model is effective and adaptable to other rare conditions.

UR - http://www.scopus.com/inward/record.url?scp=81355142674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355142674&partnerID=8YFLogxK

U2 - 10.1016/j.amepre.2011.09.021

DO - 10.1016/j.amepre.2011.09.021

M3 - Article

C2 - 22099354

AN - SCOPUS:81355142674

VL - 41

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

IS - 6 SUPPL.4

ER -